Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Anatomic Stage III Breast Cancer AJCC V8

Anatomic Stage III Breast Cancer AJCC V8

16

Pipeline Programs↗

12

Active Trials↗

9

Companies Involved↗

Anatomic Stage III Breast Cancer AJCC v8 is an emerging landscape with 16 programs across 9 companies.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

6/100

Mech. Concentration

18/100

Completion Rate

0/100

Attrition Rate

0/100

Pipeline

Programs by Phase

Preclinical6

Perflutren Lipid Microspheres

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Cyclophosphamide

Baxter Healthcare Corporation

Neoantigen Peptide Vaccine

The First Affiliated Hospital of Nanchang University

Sargramostim

Sanofi

Copanlisib Hydrochloride

National Cancer Institute (NCI)

Phase 17

Abemaciclib

Eli Lilly

BET Bromodomain Inhibitor ZEN-3694

National Cancer Institute (NCI)

Retifanlimab

Incyte

Niraparib

Glaxo Dba Glaxosmithkline

Dostarlimab

Glaxo Dba Glaxosmithkline

Phase 23

Atezolizumab

Roche

Olaparib

AstraZeneca

Talazoparib

Pfizer

Phase 3

No programs

Approved

No programs

Analysis

Modality Breakdown

16programs

Small molecule956%

Monoclonal antibody531%

Protein / enzyme16%

Vaccine16%

Modality classified for 100% of 16 pipeline programs.

Analysis

Trial Status

14

clinical trials

Active, not recruiting7 · 50%

Recruiting5 · 36%

Suspended2 · 14%

Clinical Trials

Trial Activity

14 trials

Phase 1b Study of Pidnarulex and Trastuzumab Deruxtecan in Patients With HER2 Expressing Solid Tumors

Recruiting·National Cancer Institute (NCI)·Phase 1·NCT07137416·36 enrolled

A Phase 1b Trial of ZEN003694 (ZEN-3694) With Pembrolizumab and Nab-Paclitaxel in Patients With Metastatic Triple-Negative Breast Cancer

Recruiting·National Cancer Institute (NCI)·Phase 1·NCT05422794·57 enrolled

A Phase II Trial to Evaluate Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Recruiting·UUniversity of Washington·Phase 2·NCT06179303·60 enrolled

A Phase I/II Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)

Recruiting·MMayo Clinic·Preclinical·NCT05269381·138 enrolled

A Phase 1 Study of BET Bromodomain Inhibitor ZEN003694 in Combination With the CDK4/6 Inhibitor Abemaciclib in Patients With NUT Carcinoma, Breast Cancer and Other Solid Tumors

Recruiting·National Cancer Institute (NCI)·Phase 1·NCT05372640·45 enrolled

A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer

Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT02115282·608 enrolled

Monitoring Neoadjuvant Chemotherapy of Breast Cancer Using 3D Subharmonic Aided Pressure Estimation

Active, not recruiting·—·Preclinical·NCT04715958·122 enrolled

A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab With or Without Ipilimumab in Advanced Solid Tumors

Active, not recruiting·National Cancer Institute (NCI)·Phase 1·NCT02453620·57 enrolled

A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination With Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer

Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT02849496·89 enrolled

Phase IB Trial of Niraparib and Dostarlimab (TSR-042) in Patients With BRCA-Mutated Breast, Pancreas or Ovary Cancer

Active, not recruiting·UUniversity of Washington·Phase 1·NCT04673448·18 enrolled

A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response

Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT04550494·29 enrolled

A Phase I/II Trial Evaluating the Safety and Efficacy of Eribulin in Combination With Copanlisib in Patients With Metastatic Triple Negative Breast Cancer

Active, not recruiting·National Cancer Institute (NCI)·Preclinical·NCT04345913·24 enrolled

A Phase 1 Study in Patients With Clinically Node-Positive Breast Cancer to Assess the Safety, Ultrasound Conspicuity, and Migration of an Ultrasound Twinkling Marker Obeservedfor Sonographic Targeting (UTMOST TRIAL)

Suspended·MMayo Clinic·N/A·NCT05547347·15 enrolled

Phase I Study Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer

Suspended·National Cancer Institute (NCI)·Phase 1·NCT05673200·32 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)